N. ÖZTOP Et Al. , "A real life experience of omalizumab: Nine‐year follow‐up of 205 patients in a single center.," European Academy of Allergy and Clinical Immunology Congress , 2019
ÖZTOP, N. Et Al. 2019. A real life experience of omalizumab: Nine‐year follow‐up of 205 patients in a single center.. European Academy of Allergy and Clinical Immunology Congress .
ÖZTOP, N., GELİNCİK, A., DEMİR, S., BEYAZ, Ş., tüzer, c., yeğit, o., ... BİNGÖL, Z.(2019). A real life experience of omalizumab: Nine‐year follow‐up of 205 patients in a single center. . European Academy of Allergy and Clinical Immunology Congress
ÖZTOP, NİDA Et Al. "A real life experience of omalizumab: Nine‐year follow‐up of 205 patients in a single center.," European Academy of Allergy and Clinical Immunology Congress, 2019
ÖZTOP, NİDA Et Al. "A real life experience of omalizumab: Nine‐year follow‐up of 205 patients in a single center.." European Academy of Allergy and Clinical Immunology Congress , 2019
ÖZTOP, N. Et Al. (2019) . "A real life experience of omalizumab: Nine‐year follow‐up of 205 patients in a single center.." European Academy of Allergy and Clinical Immunology Congress .
@conferencepaper{conferencepaper, author={NİDA ÖZTOP Et Al. }, title={A real life experience of omalizumab: Nine‐year follow‐up of 205 patients in a single center.}, congress name={European Academy of Allergy and Clinical Immunology Congress}, city={}, country={}, year={2019}}